Ophthalmology
Vitreous Hemorrhage
5
Pipeline Programs↗
0
Active Trials↗
3
Companies Involved↗
Vitreous Hemorrhage is an early-stage landscape with 5 programs across 3 companies. The most active players are Regeneron, Roche, Amphastar Pharmaceuticals, Inc.. 1 therapy is approved with 1 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 1
No programs
Approved1
Analysis
Modality Breakdown
6programs
Protein / enzyme350%
Monoclonal antibody233%
Small molecule117%
Modality classified for 100% of 6 pipeline programs.
Analysis
Trial Status
7
clinical trials
Completed5 · 71%
Unknown status2 · 29%
Clinical Trials
Trial Activity
7 trials
Intravitreal Aflibercept Injection or Early Vitrectomy for Diabetic Vitreous Hemorrhage
Completed·—·Phase 4·NCT04153253·34 enrolled
Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage
Unknown status·HHospital Regional de São José - Dr. Homero de Miranda Gomes·Phase 4·NCT01824043·20 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)